Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...

Cell therapy oncology drug developers Imugene and Chimeric Therapeutics have won FDA support – albeit in different ways.

Global biopharma leader CSL today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® ...

Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...

The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal ...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ...

Researchers have reported a striking result in the biology of aging: a simple pairing of two existing compounds extended the ...

The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

"UCB is proud to share these important results with the medical community at AES, especially given the significant unmet need ...

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...